🎉 M&A multiples are live!
Check it out!

PTC Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for PTC Therapeutics and similar public comparables like Pharming, Vivoryon Therapeutics, and Julphar.

PTC Therapeutics Overview

About PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.


Founded

1998

HQ

United States of America
Employees

1.0K+

Website

ptcbio.com

Financials

LTM Revenue $784M

LTM EBITDA -$192M

EV

$4.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

PTC Therapeutics Financials

PTC Therapeutics has a last 12-month revenue of $784M and a last 12-month EBITDA of -$192M.

In the most recent fiscal year, PTC Therapeutics achieved revenue of $807M and an EBITDA of -$120M.

PTC Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See PTC Therapeutics valuation multiples based on analyst estimates

PTC Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $938M $807M XXX XXX XXX
Gross Profit $654M $872M XXX XXX XXX
Gross Margin 70% 108% XXX XXX XXX
EBITDA -$330M -$120M XXX XXX XXX
EBITDA Margin -35% -15% XXX XXX XXX
Net Profit -$559M -$627M XXX XXX XXX
Net Margin -60% -78% XXX XXX XXX
Net Debt $1.0B $1.5B XXX XXX XXX

Financial data powered by Morningstar, Inc.

PTC Therapeutics Stock Performance

As of April 15, 2025, PTC Therapeutics's stock price is $45.

PTC Therapeutics has current market cap of $3.6B, and EV of $4.9B.

See PTC Therapeutics trading valuation data

PTC Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$4.9B $3.6B XXX XXX XXX XXX $-4.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

PTC Therapeutics Valuation Multiples

As of April 15, 2025, PTC Therapeutics has market cap of $3.6B and EV of $4.9B.

PTC Therapeutics's trades at 6.2x LTM EV/Revenue multiple, and -25.5x LTM EBITDA.

Analysts estimate PTC Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for PTC Therapeutics and 10K+ public comps

PTC Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $4.9B XXX XXX XXX
EV/Revenue 6.1x XXX XXX XXX
EV/EBITDA -40.6x XXX XXX XXX
P/E -9.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -26.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PTC Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

PTC Therapeutics Valuation Multiples

PTC Therapeutics's NTM/LTM revenue growth is -3%

PTC Therapeutics's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, PTC Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate PTC Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for PTC Therapeutics and other 10K+ public comps

PTC Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -14% XXX XXX XXX XXX
EBITDA Margin -15% XXX XXX XXX XXX
EBITDA Growth -64% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -18% XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 66% XXX XXX XXX XXX
Opex to Revenue 111% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

PTC Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

PTC Therapeutics M&A and Investment Activity

PTC Therapeutics acquired  XXX companies to date.

Last acquisition by PTC Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . PTC Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by PTC Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About PTC Therapeutics

When was PTC Therapeutics founded? PTC Therapeutics was founded in 1998.
Where is PTC Therapeutics headquartered? PTC Therapeutics is headquartered in United States of America.
How many employees does PTC Therapeutics have? As of today, PTC Therapeutics has 1.0K+ employees.
Who is the CEO of PTC Therapeutics? PTC Therapeutics's CEO is Dr. Matthew B. Klein, F.A.C.S.,M.D.,M.S..
Is PTC Therapeutics publicy listed? Yes, PTC Therapeutics is a public company listed on NAS.
What is the stock symbol of PTC Therapeutics? PTC Therapeutics trades under PTCT ticker.
When did PTC Therapeutics go public? PTC Therapeutics went public in 2013.
Who are competitors of PTC Therapeutics? Similar companies to PTC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of PTC Therapeutics? PTC Therapeutics's current market cap is $3.6B
What is the current revenue of PTC Therapeutics? PTC Therapeutics's last 12-month revenue is $784M.
What is the current EBITDA of PTC Therapeutics? PTC Therapeutics's last 12-month EBITDA is -$192M.
What is the current EV/Revenue multiple of PTC Therapeutics? Current revenue multiple of PTC Therapeutics is 6.2x.
What is the current EV/EBITDA multiple of PTC Therapeutics? Current EBITDA multiple of PTC Therapeutics is -25.5x.
What is the current revenue growth of PTC Therapeutics? PTC Therapeutics revenue growth between 2023 and 2024 was -14%.
Is PTC Therapeutics profitable? Yes, PTC Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.